HK1225735A1 - 絲氨酸/蘇氨酸激酶抑制劑 - Google Patents
絲氨酸/蘇氨酸激酶抑制劑Info
- Publication number
- HK1225735A1 HK1225735A1 HK16114196A HK16114196A HK1225735A1 HK 1225735 A1 HK1225735 A1 HK 1225735A1 HK 16114196 A HK16114196 A HK 16114196A HK 16114196 A HK16114196 A HK 16114196A HK 1225735 A1 HK1225735 A1 HK 1225735A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- serine
- kinase inhibitors
- threonine kinase
- threonine
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361922042P | 2013-12-30 | 2013-12-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1225735A1 true HK1225735A1 (zh) | 2017-09-15 |
Family
ID=52347479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16114196A HK1225735A1 (zh) | 2013-12-30 | 2016-12-14 | 絲氨酸/蘇氨酸激酶抑制劑 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9670208B2 (zh) |
| EP (1) | EP3089980B1 (zh) |
| JP (1) | JP6642942B2 (zh) |
| KR (1) | KR102396710B1 (zh) |
| CN (1) | CN105980387B (zh) |
| BR (1) | BR112016015236B1 (zh) |
| CA (1) | CA2934709C (zh) |
| HK (1) | HK1225735A1 (zh) |
| MX (1) | MX2016008624A (zh) |
| WO (1) | WO2015103137A1 (zh) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3321262T (lt) * | 2012-03-01 | 2021-06-10 | Array Biopharma, Inc. | Serino/treonino kinazės inhibitoriai |
| WO2014060395A1 (en) | 2012-10-16 | 2014-04-24 | F. Hoffmann-La Roche Ag | Serine/threonine kinase inhibitors |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| MX368443B (es) | 2013-12-06 | 2019-10-02 | Genentech Inc | Inhibidores de serina/treonina cinasa. |
| EP3089788B1 (en) | 2013-12-30 | 2018-10-24 | Genentech, Inc. | Serine/threonine kinase inhibitors |
| CA2993018A1 (en) | 2015-07-20 | 2017-01-26 | Genzyme Corporation | Colony stimulating factor-1 receptor (csf-1r) inhibitors |
| LT3374359T (lt) | 2015-11-09 | 2020-03-25 | Astrazeneca Ab | Dihidroimidazopirazinono deriniai, tinkami panaudoti vėžio gydymui |
| KR20180134347A (ko) | 2016-04-15 | 2018-12-18 | 제넨테크, 인크. | 암의 진단 및 치료 방법 |
| CN107383002B (zh) * | 2016-05-17 | 2021-07-13 | 中国科学院上海药物研究所 | 一类含氟三氮唑并吡啶类化合物及其制备方法、药物组合物和用途 |
| CN109790166A (zh) | 2016-06-20 | 2019-05-21 | 诺华股份有限公司 | 咪唑并吡啶化合物用于治疗癌症 |
| WO2017221092A1 (en) * | 2016-06-20 | 2017-12-28 | Novartis Ag | Triazolopyridine compounds and uses thereof |
| US11091489B2 (en) | 2016-06-20 | 2021-08-17 | Novartis Ag | Crystalline forms of a triazolopyrimidine compound |
| EP3527570A4 (en) | 2016-10-14 | 2020-04-15 | Jiangsu Hengrui Medicine Co., Ltd. | FIVE-LINKED HETERARYARYLE CYCLE BRIDGE DERIVATIVE, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF |
| EP3679159A1 (en) | 2017-09-08 | 2020-07-15 | H. Hoffnabb-La Roche Ag | Diagnostic and therapeutic methods for cancer |
| US11937503B2 (en) | 2017-11-30 | 2024-03-19 | Universal Display Corporation | Organic electroluminescent materials and devices |
| EP3752200A1 (en) | 2018-02-13 | 2020-12-23 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| CN110627775A (zh) * | 2019-10-24 | 2019-12-31 | 嘉兴特科罗生物科技有限公司 | 一种小分子化合物 |
| CN112159421A (zh) * | 2020-10-10 | 2021-01-01 | 珠海奥博凯生物医药技术有限公司 | 一种2-氟-4-甲基-3-吡啶硼酸的制备方法 |
| EP4267573A1 (en) | 2020-12-23 | 2023-11-01 | Genzyme Corporation | Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2714880A1 (de) | 1977-04-02 | 1978-10-26 | Hoechst Ag | Cephemderivate und verfahren zu ihrer herstellung |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| EP1401836B1 (en) | 2001-06-21 | 2006-08-23 | SmithKline Beecham Corporation | Imidazo¬1,2-a|pyridine derivatives for the prophylaxis and treatment of herpes viral infections |
| US6921762B2 (en) * | 2001-11-16 | 2005-07-26 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| US7629342B2 (en) | 2005-06-17 | 2009-12-08 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
| JP2009001551A (ja) | 2007-05-18 | 2009-01-08 | Sumitomo Chemical Co Ltd | 有機硫黄化合物及びその有害節足動物防除用途 |
| EP2681215B1 (en) * | 2011-02-28 | 2015-04-22 | Array Biopharma, Inc. | Serine/threonine kinase inhibitors |
| MX340756B (es) | 2011-08-04 | 2016-07-25 | Array Biopharma Inc | Compuestos de quinazolina como inhibidores de serina/treonina quinasa. |
| LT3321262T (lt) | 2012-03-01 | 2021-06-10 | Array Biopharma, Inc. | Serino/treonino kinazės inhibitoriai |
| RU2644947C2 (ru) | 2012-08-27 | 2018-02-15 | Аррэй Байофарма Инк. | Ингибиторы серин/треонин киназы для лечения гиперпролиферативных заболеваний |
| US9532987B2 (en) * | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| MX368443B (es) * | 2013-12-06 | 2019-10-02 | Genentech Inc | Inhibidores de serina/treonina cinasa. |
| EP3089788B1 (en) | 2013-12-30 | 2018-10-24 | Genentech, Inc. | Serine/threonine kinase inhibitors |
-
2014
- 2014-12-29 KR KR1020167020608A patent/KR102396710B1/ko active IP Right Grant
- 2014-12-29 BR BR112016015236-0A patent/BR112016015236B1/pt active IP Right Grant
- 2014-12-29 WO PCT/US2014/072555 patent/WO2015103137A1/en active Application Filing
- 2014-12-29 MX MX2016008624A patent/MX2016008624A/es active IP Right Grant
- 2014-12-29 EP EP14827387.3A patent/EP3089980B1/en active Active
- 2014-12-29 CA CA2934709A patent/CA2934709C/en active Active
- 2014-12-29 JP JP2016543584A patent/JP6642942B2/ja active Active
- 2014-12-29 CN CN201480074279.6A patent/CN105980387B/zh active Active
-
2016
- 2016-06-29 US US15/197,445 patent/US9670208B2/en active Active
- 2016-12-14 HK HK16114196A patent/HK1225735A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016015236A8 (pt) | 2018-04-24 |
| MX2016008624A (es) | 2017-01-06 |
| JP2017502049A (ja) | 2017-01-19 |
| EP3089980B1 (en) | 2018-01-31 |
| CA2934709C (en) | 2022-08-30 |
| CN105980387A (zh) | 2016-09-28 |
| KR102396710B1 (ko) | 2022-05-10 |
| US20160304519A1 (en) | 2016-10-20 |
| CA2934709A1 (en) | 2015-07-09 |
| WO2015103137A1 (en) | 2015-07-09 |
| JP6642942B2 (ja) | 2020-02-12 |
| BR112016015236A2 (pt) | 2018-01-23 |
| US9670208B2 (en) | 2017-06-06 |
| KR20160104036A (ko) | 2016-09-02 |
| EP3089980A1 (en) | 2016-11-09 |
| BR112016015236B1 (pt) | 2023-11-14 |
| CN105980387B (zh) | 2019-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1254429A1 (zh) | 絲氨酸/蘇氨酸激酶抑制劑 | |
| HK1225735A1 (zh) | 絲氨酸/蘇氨酸激酶抑制劑 | |
| HK1223877A1 (zh) | 絲氨酸/蘇氨酸激酶抑制劑 | |
| HK1220459A1 (zh) | 激酶抑制劑 | |
| HK1217198A1 (zh) | 蛋白激酶抑制劑 | |
| HK1211578A1 (zh) | 作為 激酶抑制劑的酰氨基咪唑並噠嗪 | |
| HK1214813A1 (zh) | 激酶抑制劑 | |
| HK1219104A1 (zh) | 激酶抑制劑 | |
| ZA201604461B (en) | Serine/threonine kinase inhibitors | |
| HK1211574A1 (zh) | 絲氨酸/蘇氨酸激酶抑制劑 | |
| HK1218119A1 (zh) | 蛋白激酶抑制劑 | |
| EP2968358A4 (en) | NOVEL CHOLINKINASE INHIBITORS | |
| HK1218263A1 (zh) | 大環 激酶抑制劑 | |
| EP2968331A4 (en) | PYRROLOPYRIMIDINE COMPOUNDS AS KINASEINHIBITORS | |
| EP2999472A4 (en) | INHIBITORS OF AURORA KINASE | |
| HK1222386A1 (zh) | 作爲詹納斯激酶的抑制劑的 -氰基甲基酰胺 | |
| GB201307155D0 (en) | Kinase inhibitors | |
| GB201323021D0 (en) | Use of kinase inhibitors | |
| GB201321227D0 (en) | Use of kinase inhibitors | |
| GB201304714D0 (en) | Macrocyclic RIP2 Kinase inhibitors |